cvot tirzepatide 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What Diabetes Distilled: SURPASS-CVOT – Tirzepatide

Collect patient testimonials and before/after data (with consent) to fuel future marketing for your medical weight loss program

Food and Drug Administration and is currently marketed in various dosage strengths and forms as Mounjaro and Zepbound

The SmPC advises monitoring renal function if severe gastrointestinal adverse reactions occur

The process is best described in the last publication comparing the WOBASZ study findings in the population aged 2074

Your initial consultation will include a comprehensive health evaluation, including a review of your medical history, metabolic testing, and body composition analysis